Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling

• Asıl Yazarlar: Yuan Chen (Yazar), Fang Ma (Yazar), Nicholas Jones (Yazar), Rong Deng (Yazar), Chunze Li (Yazar), Chi‐Chung Li (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2024-02-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Mosunetuzumab is a CD3/CD20 bispecific antibody. As an on‐target effect, transient elevation of interleukin‐6 (IL‐6) occurs in early treatment cycles. A physiologically‐based pharmacokinetic (PBPK) model was developed to assess potential drug interaction caused by IL‐6 enzyme suppression on...